Olmesartan Medoxomil/Amlodipine Accord Healthcare Ireland (Olmesartan Medoxomil, Amlodipine)

Olmesartan medoxomil and amlodipine is used in the management of cardiovascular conditions that involve elevated blood pressure.

• Hypertension: improves blood pressure control when monotherapy is insufficient.
• Chronic kidney disease with hypertension: slows progression of renal impairment.
• Heart failure with preserved ejection fraction: assists in afterload reduction and symptom management.
• Post‑myocardial infarction hypertension: helps maintain target blood pressure to reduce recurrent events.
• High‑risk cardiovascular patients: contributes to overall cardiovascular risk reduction when combined with lifestyle measures.

• Olmesartan medoxil binds selectively to angiotensin II type 1 (AT1) receptors, blocking the vasoconstrictive and aldosterone‑secreting effects of angiotensin II. Amlodipine, a dihydropyridine calcium‑channel blocker, inhibits calcium influx into vascular smooth‑muscle cells, causing arterial vasodilation. The combined action reduces systemic vascular resistance and lowers blood pressure more effectively than either component alone.

Common Side Effects

• Peripheral edema: mild swelling of the ankles or feet.
• Headache: transient, often resolves with continued therapy.
• Dizziness: especially upon standing quickly.
• Flushing: warm sensation, typically short‑lived.
• Fatigue: general tiredness without other cause.
• Palpitations: awareness of heartbeat, usually benign.

Serious or Rare Side Effects

• Angio‑edema: rapid swelling of face, lips, tongue, or throat.
• Severe hypotension: marked drop in blood pressure causing fainting.
• Hepatic dysfunction: elevated liver enzymes or jaundice.
• Acute kidney injury: sudden reduction in renal function.
• Myocardial infarction: rare occurrence of heart attack.
• Blood dyscrasias: abnormal blood counts such as neutropenia.

Before initiating therapy, evaluate patient history and concomitant medications.

• Renal impairment: adjust dose and monitor kidney function regularly.
• Hepatic disease: use with caution; monitor liver enzymes.
• Electrolyte disturbances: check potassium and sodium levels.
• Pregnancy: avoid use; drug is contraindicated in the second and third trimesters.
• Elderly patients: start at lower dose and titrate slowly.
• Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Olmesartan medoxomil/amlodipine may interact with several drug classes.

Major Interactions (Avoid)

• Potassium‑rich supplements or potassium‑sparing diuretics: risk of hyper‑kalemia.
• Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): increase amlodipine levels.
• NSAIDs (high dose): may blunt antihypertensive effect and affect renal function.

Moderate Interactions (Monitor Closely)

• Diuretics: may enhance hypotensive effect, requiring dose adjustment.
• Lithium: increased lithium levels, monitor serum concentrations.
• Antidiabetic agents: may require adjustment of glucose‑lowering therapy.